貴州三力(603439.SH):控股股東擬轉讓5.1244%股份給悦欣醫藥
格隆匯8月12日丨貴州三力(603439.SH)公佈,公司於近日接到控股股東、實際控制人張海先生通知,獲悉張海先生與悦欣醫藥於2024年8月11日簽署了《股份轉讓協議》,將其持有的公司無限售流通股21,000,000股股份(佔公司總股本的5.1244%)通過協議轉讓的方式,以每股10.50元的價格轉讓給悦欣醫藥,轉讓價款合計為人民幣220,500,000.00元。本次權益變動不會導致公司控股股東及實際控制人發生變化。過户完成後,悦欣醫藥將成為公司新的持股5%以上非第一大股東。其本次需支付的股份轉讓價款全部來源於自有資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.